What it is
Every U.S. state requires newborn blood-spot screening. The specific panel varies but follows the federal Recommended Uniform Screening Panel (RUSP). Early detection of these disorders allows treatment (special formula, hormones, enzyme therapy) that prevents intellectual disability, organ damage, or death. A positive screen is not a diagnosis — it means a confirmatory test is needed.
Evidence review links
Each link opens the full review on the publisher's site in a new tab.
Possible benefits
- Catches rare, treatable disorders before symptoms appear — outcomes are dramatically better with early treatment[HRSA / Advisory Committee on Heritable Disorders in Newborns and Children↗][American Academy of Pediatrics↗]
- Same heel prick usually covers 30+ conditions[HRSA / Advisory Committee on Heritable Disorders in Newborns and Children↗]
- Legally required or offered by every U.S. state[HRSA / Advisory Committee on Heritable Disorders in Newborns and Children↗]
Possible risks
- Brief pain at the heel prick — can be reduced by breastfeeding, skin-to-skin, or sucrose during the draw[American Academy of Pediatrics↗]
- False positives are common; a positive screen requires confirmatory testing and can cause parental anxiety[American Academy of Pediatrics↗]
Alternatives
- Do the draw during breastfeeding or skin-to-skin for pain control[American Academy of Pediatrics↗]
- Declining is possible in most states with a written refusal, but strongly discouraged — many missed diagnoses are permanent[HRSA / Advisory Committee on Heritable Disorders in Newborns and Children↗]
Current evidence
The HRSA-maintained RUSP lists 37 core and 26 secondary conditions. Every U.S. state screens for most or all core conditions. Early treatment for PKU, congenital hypothyroidism, and MCAD prevents severe disability and death.
Where the evidence is clear · where people may choose differently
For most topics, guidelines from ACOG, WHO, and other major bodies broadly agree on the core safety points (when to act in an emergency, informed-consent standards, monitoring baselines). Where reasonable people — and even guidelines — differ tends to be around thresholds (when to start or stop something), preferences (comfort, environment, support), and values (how you weigh small risks against benefits). Use the questions below to explore those pieces with your care team.
Educational only. Your care team can help you weigh what applies to your specific situation.
Related evidence topics
- Newborn Hearing ScreenA painless test done during the hospital stay — either OAE (otoacoustic emissions) or ABR (auditory brainstem response) — that catches hearing loss early so language development can be supported from the start.
- Critical Congenital Heart Disease (CCHD) Pulse Ox ScreenA pulse oximeter clipped to the baby's hand and foot at ≥24 hours old, screening for serious heart defects that can be missed on physical exam and prenatal ultrasound.
- Jaundice and Bilirubin MonitoringYellowing of the baby's skin and eyes from bilirubin — extremely common in the first week. Most cases are mild; a few need phototherapy to prevent rare brain injury (kernicterus).
Questions to ask your care team
- ?What's on our state's panel?
- ?Can the draw happen during breastfeeding or skin-to-skin?
- ?How and when will we get results — and who calls if something is positive?
- ?If a screen is positive, what's the confirmatory test?
Universal questions (works for any decision)
A short BRAIN-style set you can bring to any conversation about interventions, monitoring, or care decisions.
- ?Why are you recommending this now — is it urgent, routine, or optional?
- ?What happens if we wait an hour (or longer) before deciding?
- ?What signs would tell us this is working — or that we need to change course?
- ?What are the alternatives, including doing nothing?
- ?What would you recommend if this were your family?
- ?What would change your recommendation?
Sources & provenance
Tap a source to open the original guideline or review in a new tab.
- Recommended Uniform Screening Panel (RUSP) — HRSA / Advisory Committee on Heritable Disorders in Newborns and Children
- AAP: Newborn Screening Expands — American Academy of Pediatrics
Plain-language paraphrase. Re-verify before publish.
Last reviewed: 2026-07-03
Further reading — canonical references
Read the source material directly. Each link opens the publisher's own current guidance in a new tab — cross-check what we summarize against what they say.
Tier 1 · Clinical guidelines
Tier 2 · Systematic reviews
Tier 3 · Childbirth-specific
Educational only. Guidelines evolve — the linked publisher pages will reflect newer guidance than any static snapshot.
Version history — v1.0.0
v1.0.0 · 2026-07-03 · LlaMamma editors
Initial newborn blood-spot screening topic.
New guidance from ACOG, WHO, Evidence Based Birth, or other listed sources is recorded here and can be updated remotely without a new app release.